Yong Carmen S M, Dardalhon Valerie, Devaud Christel, Taylor Naomi, Darcy Phillip K, Kershaw Michael H
Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Department of Medicine, Institut de Génétique Moléculaire de Montpellier, Montpellier, France.
Immunol Cell Biol. 2017 Apr;95(4):356-363. doi: 10.1038/icb.2016.128. Epub 2016 Dec 22.
The potential for immunotherapy as a treatment option for cancer is clear from remarkable responses of some leukemia patients to adoptive cell transfer using autologous T cells genetically modified to express chimeric antigen receptors (CARs). However, the vast majority of cancers, in particular the more common solid cancers, such as those of the breast, colon and lung, fail to respond significantly to infusions of CAR T cells. Solid cancers present some formidable barriers to adoptive cell transfer, including suppression of T-cell function and inhibition of T-cell localization. In this review, we discuss the current state of CAR T-cell therapy in solid cancers, the variety of concepts being investigated to overcome these barriers as well as approaches aimed at increasing the specificity and safety of adoptive cell transfer.
免疫疗法作为癌症治疗选择的潜力，从一些白血病患者对使用经基因改造以表达嵌合抗原受体（CAR）的自体T细胞进行过继性细胞转移的显著反应中可见一斑。然而，绝大多数癌症，尤其是更常见的实体癌，如乳腺癌、结肠癌和肺癌，对CAR T细胞输注的反应并不显著。实体癌对过继性细胞转移存在一些巨大障碍，包括T细胞功能的抑制和T细胞定位的抑制。在本综述中，我们讨论了实体癌中CAR T细胞疗法的现状、为克服这些障碍而正在研究的各种概念，以及旨在提高过继性细胞转移的特异性和安全性的方法。
